Innovation

Radio-Halogenated Nortropanes for Imaging Serotonin Transporters

Emory University
posted on 07/07/2009

Applications

Imaging of serotonin transporters for drug development and research pertaining to central nervous system (CNS) diseases and disorders.

Highlights
  • Diagnostic imaging agents bind with high affinity to the serotonin transporter (SERT).
  • Useful for measuring neuronal function in the brain of patients suffering from various diseases and disorders of the CNS including major depression, obsessive compulsive disorder and drug addiction.
Technical Summary

The serotonin and norepinephrine transporters are proteins that reside on the membrane of the nerve terminals of the serotoninergic neurons. The SERT removes serotonin from the synapse, a process which helps regulate CNS neurotransmission. This transporter has been convincingly implicated in the pathophysiology of major depression and represents the putative site of action for the majority of antidepressant medications. In addition, abnormalities in SERT density in the midbrain and frontal cortex have also been associated with obsessive compulsive disorder. Supporting evidence or the role of SERT in these diseases, however, has been predominantly collected in heterogeneous cell models of transporter function and from post-mortem human tissue.

The present invention describes halogen-labeled compounds in the 4-fluoroalkyl-3-halophenyl nortropane family that can be used to image serotonin receptor function in vivo.These compounds use a fluoride isotope that gives the labeled compounds a more useful half-life and higher resolution than previous studies performed with carbon isotopes. The nortropanes demonstrate pronounced brain uptake, low non-specific binding and high SERT selectivity and affinity. The compounds can be used to diagnose major affective disorders and may be used to differentiate for example, depression from other psychiatric disorders.

Product Development
  • Proof-of-principle has been demonstrated in a cell culture model as well as in vivo in a rat model.


Innovation Details
 

File Number: 99041 


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact Cale Lennon at Emory University for more information.

Request more info via email request more info
People

Principal Investigator:

Mark Goodman Mark Goodman

Innovations (9)

Publications (7)



Co-Investigators:

Ping Chen Ping Chen

Innovations (2)

Case Manager:

Cale Lennon Cale Lennon

Innovations (37)

Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

4,461 members 13,003 innovations 112 organizations

Browse

Linda L. Restifo, M.D., Ph.D. - University of Arizona

"I want to say again how happy I am about the iBridge Network mechanism. This seems ideal for NeuronMetrics and I'm very pleased we will be part of this venture."  read more...